百亿调仓压力袭来！寒武纪短线调整超20%

Core Insights - The recent adjustment of the Sci-Tech Innovation 50 Index by the China Securities Index Company has significant implications for the stock of Cambrian Biologics, which has exceeded the weight limit set by the index rules [1][2] - Cambrian's stock price has experienced a decline of 20% over five consecutive trading days due to the pressure from index fund rebalancing [1] Group 1: Index Adjustment and Weight Limit - The Sci-Tech Innovation 50 Index has a rule that limits the weight of a single sample to a maximum of 10%, and Cambrian's weight reached 14.88%, exceeding the limit by 5 percentage points [1] - The top five samples' combined weight must not exceed 40%, but the current combined weight stands at 45.70% [1] Group 2: Fund Rebalancing Impact - Funds tracking the Sci-Tech Innovation 50 Index, with a total scale of approximately 180 billion yuan, may need to sell nearly 10 billion yuan worth of Cambrian stock to comply with the weight limit [2] - The presence of multiple ETFs among Cambrian's top shareholders exacerbates the impact of the rebalancing on its stock price [2]